Veracyte Inc (VCYT) Jumps On New Aetna Inc. (AET) Deal: Is It A Good Stock To Buy?

How have hedgies been trading Veracyte Inc (NASDAQ:VCYT)?

According to our database, Clough Capital Partners, managed by Charles Clough, holds the number one position in Veracyte Inc (NASDAQ:VCYT). Clough Capital Partners has a $7.8 million position of about 1.07 million shares, comprising 0.3% of its 13F portfolio. On Clough Capital Partners’ heels is Consonance Capital Management, managed by Mitchell Blutt, which held a $1.7 million position of 235,860 shares; the fund has 0.2% of its 13F portfolio invested in the stock. Other peers that are bullish consist of Israel Englander’s Millennium Management, Bihua Chen’s Cormorant Asset Management, and Jeffrey Jay and David Kroin’s Great Point Partners.

Consequently, key hedge funds were breaking ground themselves. The aforementioned Consonance Capital Management assembled the biggest new position in Veracyte Inc (NASDAQ:VCYT), as its $1.7 million investment was made entirely in the first quarter.

Due to the new deal with Aetna Inc. (NYSE:AET) and seeing more interest from more hedge funds with long positions in the stock, Veracyte Inc (NASDAQ:VCYT) appears to be a good stock to buy at the moment, though the window to enter may be closing as shares appreciate rapidly, now up by over 50% in the second quarter.

Disclosure: None